IMABI-Mab

IMAB Stock Price, Valuation & Chart | I-Mab

Compare

$2.880-0.02 (-0.69%)

At close · 17 Mar 2026, 01:30 pm

Sector: Healthcare Industry: Biotechnology IMAB intrinsic value IMAB calculated fair value vs price

Overview Financials Dividends Ratios

IMAB Historical price chart

IMAB Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization542.01M

PE Ratio-5.65

EPS-0.51

Trading Volume892.60K

Today's High/Low3.01/2.81

Dividend Yield0.00

52 Week High/Low6.79/0.59

Shares Outstanding188.20M

IMAB Financial Statement

IMAB Analyst ratings

IMAB Analysis & performance metrics

IMAB Company profile

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a…

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone…

IMAB Management team

Name

Position

Tyler EhlerCTO

Senior Director of Investor Relations

Skelton JosephCFO

Chief Financial Officer

Xi-Yong Fu M.B.A., Ph.D.CEO

Chief Executive Officer & Director

Phillip Dennis M.D., Ph.D.

Chief Medical Officer

Name

Position

Tyler EhlerCTO

Senior Director of Investor Relations

Skelton JosephCFO

Chief Financial Officer

Xi-Yong Fu M.B.A., Ph.D.CEO

Chief Executive Officer & Director

Phillip Dennis M.D., Ph.D.

Chief Medical Officer

Management Team

Tyler EhlerCTO

Senior Director of Investor Relations

Skelton JosephCFO

Chief Financial Officer

Xi-Yong Fu M.B.A., Ph.D.CEO

Chief Executive Officer & Director

Phillip Dennis M.D., Ph.D.

Chief Medical Officer

Management

Tyler EhlerCTO

Senior Director of Investor Relations

Skelton JosephCFO

Chief Financial Officer

Xi-Yong Fu M.B.A., Ph.D.CEO

Chief Executive Officer & Director

Phillip Dennis M.D., Ph.D.

Chief Medical Officer

Total 4 executives

IMAB Frequently asked questions

What is I-Mab (IMAB) Stock Price?

Current stock price of I-Mab (IMAB) stock is $2.880. The stock price is -0.69% lower in the session. The intraday range can be seen from this page. Volume of I-Mab (IMAB) stock is 892.60K.

Last updated at 17 Mar 2026, 01:30 pm.

Why is the I-Mab (IMAB) stock price going up or down today?

The stock price of I-Mab (IMAB) can change with earnings, company news, and overall market sentiment. I-Mab operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the I-Mab stock expensive at its current price?

Whether I-Mab looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for IMAB on this page is -5.65. EPS on this page is -0.51. Compare those figures with peers and growth expectations before deciding if the current I-Mab price is justified.

How has the stock price of I-Mab (IMAB) performed historically?

Historical performance for I-Mab (IMAB) is shown on the price chart on this page. Review multi-period moves alongside volume to see how IMAB reacted to past earnings and market events.

Should I buy I-Mab (IMAB) stock, at this price?

Buying I-Mab (IMAB) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.